Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...

Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of esophageal cancer in a late-stage trial. The trial was studying Merck's ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass.

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...